ϳԹ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • ϳԹ News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Apr 24 2026

Full Issue

EU Approves World's 1st Combo Covid/Flu Shot That Hit Hurdle In US

According to BioSpace, Moderna withdrew its approval application in the United States last May for the vaccine, which will carry the brand name mCOMBRIAX. The timeline for resubmission with the FDA remains uncertain.

Moderna has secured the European Commission’s go-ahead for its combination flu and COVID-19 vaccine, handing the mRNA specialist a much-needed regulatory win after a rough few months of dealing with the U.S. FDA. The shot, which will carry the brand name mCOMBRIAX, combines the next-generation COVID-19 vaccine mNEXSPIKE and the investigational flu vaccine mRNA-1010. The European approval covers its use across all 27 European Union member states—plus Iceland, Liechtenstein and Norway—for the active immunization of people 50 years and up, according to a Tuesday company release. (Manalac, 4/22)

More international health news —

Four years ago, Dr. Brandon Williams, an internal-medicine doctor at a hospital in La Jolla, Calif., reached a breaking point. An increase in patients, not enough medical staff, the threat of malpractice lawsuits, and distress about patients’ inability to pay for healthcare got so bad that he developed post-traumatic stress disorder. One of his colleagues died by suicide. He didn’t want to stop practicing medicine—but he wanted to stop practicing medicine in the United States. He and his wife, Ellen Williams, 38, started looking in Europe for a better option. Then he got a letter from a medical recruiter in New Zealand. (Keates, 4/23)

Federal health officials reported on Monday that cases of a flesh-eating parasitic infection continue to be detected near the United States. The U.S. Department of Agriculture (USDA) said a New World screwworm case was confirmed in the Mexican state of Nuevo León, approximately 62 miles from the Texas border. This marks the northernmost active case in Mexico. USDA said the current risk to livestock, other animals and people in the U.S. remains very low and there is currently no evidence of NWS among animals in the U.S. (Kekatos and Joseph, 4/22)

DNA and other confidential health data from 500,000 people who volunteered for a massive U.K. health study were offered for sale online in China following a data breach this week, the British government said Thursday. The information from the U.K. Biobank database was found listed for sale on the website Alibaba, but names, addresses, contact details or telephone numbers were not included, the technology minister, Ian Murray, told lawmakers. Murray said he could not give a complete guarantee that nobody could be identified as the data could include gender, age, month and year of birth, socioeconomic status, lifestyle habits, and measures from biological samples. (Pylas, 4/23)

Norway plans to restrict access to social media for children under 16, joining a growing number of countries responding to concerns about the potential harm kids face online. The bill comes after “overwhelming” demand from the public, the government said Friday. It plans to bring the legislation to parliament before the end of the year. The limit will apply up until January 1 the year a child turns 16 with technology companies responsible for age verification, the government said. (Lundgren and Taksdal Skjeseth, 4/24)

A Brazilian gang founded in the country’s violent prisons is fast becoming one of the world’s biggest criminal organizations, reshaping global cocaine flows from South America to Europe’s busiest ports and edging into the U.S. Long under Washington’s radar, the First Capital Command, known by its Portuguese initials PCC, started out as a disgruntled band of inmates fighting for soap and toilet paper in the 1990s. (Pearson, 4/20)

The House of Mercy hospice looks after the abandoned and the ill, along with people driven from their homes by the fighting. In the chaos of war, it is a center of care, and of prayer. (Didur and Vinograd, 4/23)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • ϳԹ
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF